Literature DB >> 23980640

Five-year oncological outcomes of endoscopic extraperitoneal radical prostatectomy (EERPE) for prostate cancer: results from a medium-volume UK centre.

S Alan McNeill1, Daniel W Good, Grant D Stewart, Jens-Uwe Stolzenburg.   

Abstract

OBJECTIVE: To determine the 5-year oncological outcomes of endoscopic extraperitoneal radical prostatectomy (EERPE) from a medium-volume centre, thereby providing much needed data on outcomes from the UK. PATIENTS AND METHODS: From January 2006 to January 2012, 575 patients underwent EERPE for localized prostate cancer, performed by a single surgeon who had completed a modular training programme. Follow-up was as per local hospital policy and data were collected in our prospective database. A retrospective review of patient demographics, prostate-specific antigen (PSA) levels, pathological T stages, Gleason scores, surgical margin status and biochemical recurrence (BCR) data was performed. BCR was defined as PSA >0.2 μg/L.
RESULTS: The mean (range) patient age was 62 (40.3-76.5) years and the mean (range) follow-up was 30 (12-72) months. The median (interquartile range [IQR]) operating time was 135 (120-170) min and the median (IQR) blood loss was 200 (100-250) mL. Of the 575 patients, 135 (23.5%) had positive surgical margins (PSMs). The PSM rate for pT2 disease was 66/406 patients (16.3%) and for pT3 disease it was 68/168 patients (40.5%). Overall BCR-free survival at 5-years was 81.5%. Multivariate Cox analysis showed that PSMs, Gleason score, D'Amico risk category and pT stage were independent predictors of BCR-free survival.
CONCLUSIONS: This assessment of the oncological results of EERPE, which included the surgical learning curve, shows that the adoption of EERPE after mentored fellowship training translates into mid-term oncological outcomes in line with those of retropubic/transperitoneal laparoscopic approaches and with large-volume centres worldwide which have pioneered laparoscopic radical prostatectomy. The study shows that EERPE in a medium-volume second generation laparoscopic centre (that introduced EERPE after adequate training in pioneering centres) produces results with good 5-year oncological outcomes, similar to those of other major series, for patients in the UK.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  EERPE; mentored fellowship; oncological outcomes; prostate cancer

Mesh:

Year:  2013        PMID: 23980640     DOI: 10.1111/bju.12260

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

Review 1.  [Laparascopic radical prostatectomy].

Authors:  R Ganzer; M Do; B P Rai; A Dietel; J-U Stolzenburg
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

2.  Laparoscopic radical prostatectomy with bladder neck preservation: positive surgical margin and urinary continence status.

Authors:  Tomasz Golabek; Jaroslaw Jaskulski; Piotr Jarecki; Przemysław Dudek; Tomasz Szopiński; Piotr Chłosta
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-09-05       Impact factor: 1.195

3.  Tissue quality assessment using a novel direct elasticity assessment device (the E-finger): a cadaveric study of prostatectomy dissection.

Authors:  Daniel W Good; Ashfaq Khan; Steven Hammer; Paul Scanlan; Wenmiao Shu; Simon Phipps; Simon H Parson; Grant D Stewart; Robert Reuben; S Alan McNeill
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

4.  The influence of previous robotic experience in the initial learning curve of laparoscopic radical prostatectomy.

Authors:  José Anastácio Dias; Marcos F Dall'oglio; João Roberto Colombo; Rafael F Coelho; William Carlos Nahas
Journal:  Int Braz J Urol       Date:  2017 Sep-Oct       Impact factor: 1.541

5.  Surgical margin status and its impact on prostate cancer prognosis after radical prostatectomy: a meta-analysis.

Authors:  Lijin Zhang; Bin Wu; Zhenlei Zha; Hu Zhao; Jun Yuan; Yuefang Jiang; Wei Yang
Journal:  World J Urol       Date:  2018-05-15       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.